TWI749367B - Cd200r促效劑抗體及其用途 - Google Patents

Cd200r促效劑抗體及其用途 Download PDF

Info

Publication number
TWI749367B
TWI749367B TW108132514A TW108132514A TWI749367B TW I749367 B TWI749367 B TW I749367B TW 108132514 A TW108132514 A TW 108132514A TW 108132514 A TW108132514 A TW 108132514A TW I749367 B TWI749367 B TW I749367B
Authority
TW
Taiwan
Prior art keywords
antibody
seq
amino acid
acid sequence
cd200r
Prior art date
Application number
TW108132514A
Other languages
English (en)
Chinese (zh)
Other versions
TW202024132A (zh
Inventor
史蒂芬 Ｊ 迪馬瑞斯
安佳 凱斯特
派由 梅塔
史考特 查爾斯 波特
黛安娜 伊莎貝爾 鲁伊斯
德瑞克 雷恩 威區
秀鳳 吳
Original Assignee
美商美國禮來大藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商美國禮來大藥廠 filed Critical 美商美國禮來大藥廠
Publication of TW202024132A publication Critical patent/TW202024132A/zh
Application granted granted Critical
Publication of TWI749367B publication Critical patent/TWI749367B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW108132514A 2018-09-14 2019-09-10 Cd200r促效劑抗體及其用途 TWI749367B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731204P 2018-09-14 2018-09-14
US62/731,204 2018-09-14

Publications (2)

Publication Number Publication Date
TW202024132A TW202024132A (zh) 2020-07-01
TWI749367B true TWI749367B (zh) 2021-12-11

Family

ID=68051977

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108132514A TWI749367B (zh) 2018-09-14 2019-09-10 Cd200r促效劑抗體及其用途

Country Status (27)

Country Link
US (2) US11319370B2 (enExample)
EP (1) EP3849667A1 (enExample)
JP (3) JP7185051B2 (enExample)
KR (1) KR102705378B1 (enExample)
CN (2) CN118530360A (enExample)
AR (1) AR116668A1 (enExample)
AU (1) AU2019339334B2 (enExample)
BR (1) BR112021003254A2 (enExample)
CA (1) CA3112763C (enExample)
CL (1) CL2021000606A1 (enExample)
CO (1) CO2021003093A2 (enExample)
CR (1) CR20210134A (enExample)
DO (1) DOP2021000040A (enExample)
EA (1) EA202190530A1 (enExample)
EC (1) ECSP21017619A (enExample)
IL (1) IL281442B2 (enExample)
JO (1) JOP20210048B1 (enExample)
MA (1) MA53604A (enExample)
MX (1) MX2021003026A (enExample)
MY (1) MY196156A (enExample)
NZ (1) NZ773626A (enExample)
PE (1) PE20211742A1 (enExample)
PH (1) PH12021550530A1 (enExample)
SG (1) SG11202101697YA (enExample)
TW (1) TWI749367B (enExample)
WO (1) WO2020055943A1 (enExample)
ZA (2) ZA202101246B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
WO2021243204A1 (en) * 2020-05-29 2021-12-02 23Andme, Inc. Anti-cd200r1 antibodies and methods of use thereof
AU2023251091A1 (en) * 2022-04-06 2024-10-10 Gilead Sciences, Inc. Engineered cd200r antibodies and uses thereof
CN115458048B (zh) * 2022-09-16 2023-05-26 杭州美赛生物医药科技有限公司 基于序列编解码的抗体人源化方法
IL325073A (en) 2023-06-02 2026-02-01 Aimed Bio Inc Anti-CD200R1 antibody and its uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079352A2 (en) * 2006-12-22 2008-07-03 Schering Corporation Antibodies to cd200r
US20080267967A1 (en) * 2001-05-24 2008-10-30 Gorczynski Reginald M Modulation of cd200 receptors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1482973T3 (da) * 2002-03-15 2009-12-07 Schering Corp Fremgangsmåde til modulering af CD200-receptorer
US8075884B2 (en) * 2006-01-12 2011-12-13 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
JP6012473B2 (ja) * 2010-01-11 2016-10-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
BR112012020101A2 (pt) * 2010-02-11 2018-09-25 Alexion Pharma Inc método diagnósticos e terapêuticos usando anticorpos anti-cd200.
WO2015057906A1 (en) 2013-10-16 2015-04-23 Janssen Biotech, Inc. Cd200 receptor 1 agonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080267967A1 (en) * 2001-05-24 2008-10-30 Gorczynski Reginald M Modulation of cd200 receptors
WO2008079352A2 (en) * 2006-12-22 2008-07-03 Schering Corporation Antibodies to cd200r

Also Published As

Publication number Publication date
NZ773626A (en) 2024-11-29
PH12021550530A1 (en) 2022-02-14
SG11202101697YA (en) 2021-04-29
MA53604A (fr) 2021-12-22
ZA202101246B (en) 2023-04-26
US20220251198A1 (en) 2022-08-11
JOP20210048A1 (ar) 2021-03-11
JP2024105529A (ja) 2024-08-06
CR20210134A (es) 2021-03-29
CO2021003093A2 (es) 2021-03-19
CN112739422A (zh) 2021-04-30
IL281442A (en) 2021-04-29
MX2021003026A (es) 2021-05-27
KR20210044262A (ko) 2021-04-22
CA3112763A1 (en) 2020-03-19
TW202024132A (zh) 2020-07-01
IL281442B1 (en) 2023-11-01
AU2019339334B2 (en) 2023-03-09
PE20211742A1 (es) 2021-09-06
JP2022500080A (ja) 2022-01-04
JP7490025B2 (ja) 2024-05-24
EP3849667A1 (en) 2021-07-21
AU2019339334A1 (en) 2021-03-18
ECSP21017619A (es) 2021-04-29
CN112739422B (zh) 2024-05-28
IL281442B2 (en) 2024-03-01
JP2022141959A (ja) 2022-09-29
KR102705378B1 (ko) 2024-09-12
CN118530360A (zh) 2024-08-23
MY196156A (en) 2023-03-17
US11319370B2 (en) 2022-05-03
DOP2021000040A (es) 2021-03-31
US20200087395A1 (en) 2020-03-19
AR116668A1 (es) 2021-06-02
ZA202204978B (en) 2022-09-28
JOP20210048B1 (ar) 2024-12-22
JP7185051B2 (ja) 2022-12-06
WO2020055943A1 (en) 2020-03-19
CA3112763C (en) 2024-05-14
BR112021003254A2 (pt) 2021-05-18
CL2021000606A1 (es) 2021-09-20
EA202190530A1 (ru) 2021-06-21

Similar Documents

Publication Publication Date Title
US20250277034A1 (en) Caninized Antibodies
TWI708787B (zh) Pd-1促效劑抗體及其用途
JP6833798B2 (ja) 抗ｌａｇ−３結合タンパク質
US20210403558A1 (en) Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
CN103946238B (zh) 抗ox40抗体及使用其的方法
CN110156892B (zh) 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
CN106554417B (zh) 抗ox40抗体和使用其的方法
JP7490025B2 (ja) Ｃｄ２００ｒアゴニスト抗体およびそれらの使用
CN111712518B (zh) 对免疫球蛋白样转录物3(ilt3)具有特异性的抗体及其用途
US20230002489A1 (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
JP2023521475A (ja) 抗ｏｘ４０抗体及びその使用
US20230272067A1 (en) Human monoclonal antibodies against tigit for immune related diseases
EA048233B1 (ru) Агонистические антитела к cd200r и их применение
EA052892B1 (ru) Антитела к альфа-рецептору интерлейкина-4 человека
HK40005909B (en) Anti-pd-l1 antibodies and their use as therapeutics and diagnostics